Contineum Therapeutics, Inc.

CTNM

$17.36

-1.20%

N/A-$0.21

Healthcare

Biotechnology

NASDAQ

Active Trading

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications ...

Supply Chain of CTNM

Upstream

Foundry, packaging, memory, wafers, components, and input vendors.

Upstream

Third-Party CMO (API Manufacturing)

Third-Party CMO (Drug Product Manufacturing)

Third-Party CRO (Clinical Trial Management)

Preclinical CRO Partners

Specialty Chemical / Raw Material Suppliers

Specialty Chemical Distributors (e.g., Sigma-Aldrich/Merck, Thermo Fisher)

Laboratory Equipment Suppliers

Third-Party CMO (API Manufacturing)

Contract manufacturer of active pharmaceutical ingredient (API) for clinical trial supplies of PIPE-791 and PIPE-307

Third-Party CMO (Drug Product Manufacturing)

Contract manufacturer of formulated drug product (oral small molecule) for clinical trials

Third-Party CRO (Clinical Trial Management)

Contract research organization managing Phase 1b/2 clinical trials for PIPE-791 (IPF, chronic pain) and Phase 2 VISTA trial for PIPE-307 (RRMS)

Preclinical CRO Partners

Contract research organizations for preclinical toxicology, PK/PD, and safety pharmacology studies

Specialty Chemical / Raw Material Suppliers

Suppliers of chemical building blocks, reagents, and starting materials for small molecule synthesis

Downstream

Customers, distributors, OEMs, and channels that absorb output.

Downstream

Johnson & Johnson (Janssen Pharmaceutica NV)

No commercial customers (pre-revenue, clinical-stage)

No commercial distributors (pre-revenue, clinical-stage)

Johnson & Johnson (Janssen Pharmaceutica NV)

NYSE:JNJ

Global license and development collaboration partner for PIPE-307 (M1 receptor antagonist for RRMS and MDD). J&J holds exclusive worldwide commercialization rights; Contineum receives royalties on net sales if approved.

No commercial customers (pre-revenue, clinical-stage)

Contineum has no approved products. No downstream commercial customers or distributors exist until potential future FDA/EMA approvals of PIPE-791 or PIPE-307.

No commercial distributors (pre-revenue, clinical-stage)

No distribution agreements exist. Commercial distribution would be managed through J&J's global infrastructure for PIPE-307 if approved.

Proxies

Public comparables and monitoring names used as representatives for the analysis.

Proxies

Versant Ventures

Reata Pharmaceuticals / Biogen

Pliant Therapeutics

Johnson & Johnson

NYSE:JNJ

Primary collaboration partner for PIPE-307. J&J's neuroscience pipeline and commercial infrastructure are directly tied to the success of Contineum's lead partnered asset. J&J provides downstream revenue potential through royalties.

Versant Ventures

Unconfirmed

Founding investor that incubated Contineum (as Pipeline Therapeutics) in 2018. Versant holds significant pre-IPO equity and board representation. As a private venture firm, no public ticker exists.

Reata Pharmaceuticals / Biogen

Unconfirmed

Potential public comp for IPF-focused small molecule biotech (Reata's Skyclarys) and MS therapeutics (Biogen). Contineum's PIPE-791 targets IPF, a market with high unmet need similar to areas addressed by these companies.

Pliant Therapeutics

NASDAQ:PLRX

Direct public comparable: clinical-stage biotech developing small molecule therapies for IPF (PLRX's bexotegrast is an integrin inhibitor for IPF). Similar stage, mechanism overlap in fibrosis, and same CRO/CDMO ecosystem.

Geographic

Region-level exposures that can distort the supply network.

Geographic

United States (California)

United States (New Jersey)

Global (Clinical Trial Sites)

Contineum Therapeutics (HQ San Diego, CA)

Johnson & Johnson (Janssen)

Multiple clinical trial sites (international)

United States (California)

Corporate headquarters, R&D operations, and clinical trial sites concentrated in San Diego, CA

Contineum Therapeutics (HQ San Diego, CA)NASDAQ:CTNMAll corporate and R&D functions; leased facility at 10578 Science Center Drive, San Diego

United States (New Jersey)

J&J/Janssen collaboration based in New Brunswick, NJ; governance and decision-making for PIPE-307 program

Johnson & Johnson (Janssen)NYSE:JNJGlobal license and collaboration partner for PIPE-307

Global (Clinical Trial Sites)

Phase 2 VISTA trial (PIPE-307) and Phase 2 IPF trial (PIPE-791) are international, multi-center studies exposing the company to regulatory, geopolitical, and site-level operational risks

Multiple clinical trial sites (international)Phase 2 clinical trial sites for PIPE-307 (RRMS) and PIPE-791 (IPF) located across North America, Europe, and potentially other regions

Concentration

Customer, supplier, or partner concentration exposures that can distort the supply network.

Customer

Critical

Extreme downstream concentration: 100% dependency on Johnson & Johnson/Janssen as the sole collaboration partner for PIPE-307. Contineum's only potential path to commercial revenue for PIPE-307 runs through J&J. The PIPE-307 Phase 2 VISTA trial failed to meet primary/secondary endpoints (Nov 2025), casting doubt on the collaboration's future.

Foundry

High

Single-source CMO dependency for clinical trial drug supply. The SEC 10-K (2025) confirms reliance on third-party CMOs for clinical supplies of both PIPE-791 and PIPE-307, with risk that qualifying alternate CMOs is time-consuming and costly.

Other

Critical

Single-asset pipeline concentration risk. The entire company is dependent on two Phase 2-stage assets (PIPE-791 and PIPE-307). Failure of either program would be materially detrimental. PIPE-307 already failed its Phase 2 MS endpoint.

Revenue mix

How the target's revenue mix translates into supply-chain leverage and dependency.

Collaboration Revenue (J&J License)

100.0%

Contineum has no approved products and no commercial product revenue. The company is pre-revenue with nominal collaboration revenue from its Johnson & Johnson/Janssen license agreement for PIPE-307 (which included a $50M upfront payment and potential milestones up to ~$1B). All expenditures fund R&D and clinical trials, making CRO/CDMO partnerships the critical upstream supply chain.

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer